Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities

Abstract

Epidermal growth factor receptor inhibitors (EGFRI) produce various dermatologic side effects in the majority of patients, and guidelines are crucial for the prevention and treatment of these untoward events. The purpose of this panel was to develop evidence-based recommendations for EGFRI-associated dermatologic toxicities. A multinational, interdisciplinary panel of experts in supportive care in cancer reviewed pertinent studies using established criteria in order to develop first-generation recommendations for EGFRI-associated dermatologic toxicities. Prophylactic and reactive recommendations for papulopustular (acneiform) rash, hair changes, radiation dermatitis, pruritus, mucositis, xerosis/fissures, and paronychia are presented, as well as general dermatologic recommendations when possible. Prevention and management of EGFRI-related dermatologic toxicities is critical to maintain patients’ health-related quality of life and dose intensity of antineoplastic regimens. More rigorous investigation of these toxicities is warranted to improve preventive and treatment strategies.

DOI: 10.1007/s00520-011-1197-6

Extracted Key Phrases

8 Figures and Tables

050100201220132014201520162017
Citations per Year

322 Citations

Semantic Scholar estimates that this publication has 322 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@inproceedings{Lacouture2011ClinicalPG, title={Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities}, author={Mario E. Lacouture and Milan J. Anadkat and Ren{\'e} Jean Bensadoun and Jane Claire Bryce and Alexandre Chan and Joel Epstein and Beth Eaby-Sandy and Barbara A. Murphy}, booktitle={Supportive Care in Cancer}, year={2011} }